Synthesis of process related Dapsone impurities : Selective diazotization of aromatic di-amine

Mahesh Bandishti; Balaji Chaugule; Chinmoy Pramanik; Ganesh Karhade; Ashok Chaudhari

doi:10.54647/chemistry15253

ISSN: 2995-6943

Volume 7, Number 2 (2022)

Year Launched: 2016

Journal Menu

■ About The Journal

■ Aims & Scope

■ Editorial Board

■ Article Processing Charge

■ Archive

Previous Issues

■ Volume 9, Number 2 (2024)

■ Volume 9, Number 1 (2024)

■ Volume 8, Number 3 (2023)

■ Volume 8, Number 2 (2023)

■ Volume 8, Number 1 (2023)

■ Volume 7, Number 3 (2022)

■ Volume 7, Number 2 (2022)

■ Volume 7, Number 1 (2022)

■ Volume 6, Number 2 (2021)

■ Volume 6, Number 1 (2021)

■ Volume 5, Number 4 (2020)

■ Volume 5, Number 3 (2020)

■ Volume 5, Number 2 (2020)

■ Volume 5, Number 1 (2020)

■ Volume 4, Number 5 (2019)

■ Volume 4, Number 4 (2019)

■ Volume 4, Number 3 (2019)

■ Volume 4, Number 2 (2019)

■ Volume 4, Number 1 (2019)

■ Volume 3, Number 3 (2018)

■ Volume 3, Number 2 (2018)

■ Volume 3, Number 1 (2018)

■ Volume 2, Number 3 (2017)

■ Volume 2, Number 2 (2017)

■ Volume 2, Number 1 (2017)

■ Volume 1, Number 2 (2016)

■ Volume 1, Number 1 (2016)

Synthesis of process related Dapsone impurities : Selective diazotization of aromatic di-amine

Volume 7, Issue 2, April 2022 | PP. 33-41 | PDF (216 K) | Pub. Date: April 17, 2022
DOI: 10.54647/chemistry15253 96 Downloads 161549 Views

Author(s)

Mahesh Bandishti, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India

Balaji Chaugule, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India

Chinmoy Pramanik, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India

Ganesh Karhade, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India

Ashok Chaudhari, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India

Abstract
Process related two impurities of Dapsone were synthesized by applying cu-catalyzed conversions for the impurity profile and toxicological study. Controlled mono-diazotization of Dapsone followed by insitu iodination is the key step of our synthesis.

Keywords
Non-aqueous diazotization, Ullmann reactions, Process related impurities, Impurity Profile, Isoamyl nitrite and Hydroxylation.

Cite this paper
Mahesh Bandishti, Balaji Chaugule, Chinmoy Pramanik, Ganesh Karhade, Ashok Chaudhari, Synthesis of process related Dapsone impurities : Selective diazotization of aromatic di-amine , SCIREA Journal of Chemistry. Volume 7, Issue 2, April 2022 | PP. 33-41. 10.54647/chemistry15253

References

[ 1 ]	Oelschlaeger H, Modrack H, (1986) Arch Der Pharm 319 (1), 10.
[ 2 ]	Ritter C V, Grisham M B, Granger D N,(1989) Gastroenterology , 96, 811.
[ 3 ]	Rensburg C E, Van Gatner E M, Lmkamp F M, Anderson R,(1982) Antimicrob, Agents Chemother , 21(5), 693.
[ 4 ]	Johnson L A, Wirostko E, US Patent 4 220 657 (1978).
[ 5 ]	a. Allegrini P, Napoletano C, Razzetti G, Castaldi G and US 0192929, 2008. b. Roblin R O, Williams J H,U S Patent No. 2227400, 1941. c. Weijlard J, Messelry J P, U S Patent No 2385899, 1945. d.Villa M, Faveri C D, Zanotti R, Ciardella F, Borin F, US 0293970, 2008. e. Nariman A E, Maha A H, Samia A T, Ghada A S,(2021) Acta Chromatographica, f. Adrian L, Ulrike H, (2021) Journal of Pharamaceutcal and Biomedical Analysis ,198.
[ 6 ]	a. Go¨ro¨g S (2006) Trends in Analytical Chemistry, (25) 8, 755-757. b. Rao N R, Kiran S S M, Prasanthi N L, (2010), Indian J Pharm Educ Res 44(3), 301- 310.
[ 7 ]	a) ICH Guidelines, Q3A (R2), (2006) Impurities in New Drug Substances. b) ICH Guidelines, Q3B (R2), (2006) Impurities in New Drug Products. c) ICH Guidelines Q3C (R5), (2011) Guideline for residual solvents.
[ 8 ]	a. Gannett P M, Johnson E M, Grimes M A, Myers A L, Deavers R E, Tracy T S, (2003) Journal of Labelled Compounds and radiopharmaceuticals, 46(2), 107–114. b. Mannan C A, Krol G, Kho B T,(1977) J Pharm Sci , 66(11), 1618–1623. c. Cheung A P, Lim P,( 1977)J Pharm Sci , 66(12), 1723–1726. d. Gordon G R, Ghoul D C, Peters J H, (1975) J Pharm Sci , 64(7), 1205–1207.
[ 9 ]	a. Sandmeyer T, (1884) Ber Dtsch Chem Ges, 17 (3), 1633–1635. b. Sandmeyer T,(1884) Ber Dtsch Chem Ges, 17 (4), 2650–2653.
[ 10 ]	a. Ullmann F, Bielecki J, (1901)Ber Dtsch Chem Ges,34, 2174. b. Ullmann F,(1903) Ber Dtsch Chem Ges, 36, 2382. c. Ullmann F, Sponagel P, (1905)Ber Dtsch Chem Ges, 38, 2211
[ 11 ]	Evano G, Blanchard N, Toumi,(2008) M. Chem Rev, 108, 3054-3131.
[ 12 ]	Doyle M P, Bryker W J, (1979)J Org Chem, 44, 1572.
[ 13 ]	Chang J, Liu R, Zhu H, (2009) X-ray structure analysis, 25, 73.
[ 14 ]	Matsuda A, Shinozaki M, Yamaguchi T, Homma H, Nomoto R, Miyasaka T, Watanabe Y, Abiru T,(1992) J Med Chem 35, 241-252.
[ 15 ]	Zhao D, Wu N, Zhang S, Xi Su X, Lan J, You J,(2009) Angew Chem Int Ed , 48, 8729-8732
[ 16 ]	Chen G, Chan A S C, Kwong F Y ,(2007) Tetrahedron letter,48, 473-476.
[ 17 ]	a. Buck E, Song Z J, Tschaen D, Dormer P G, Volante R P, Reider P J, (2002),Org Lett 4(9), 1623-1626, b. Sawyer J S,(2000) Tetrahedron , 56, 5045, c. Theil F, Angew Chem , (1999) Int Ed, , 38, 2345. d. Lindley J. (1984) Tetrahedron 40, 1433.